Francis Mhimbira

In the News

This content is password protected. To view it please enter your password below:

Announcement: Provision of goods and services to IHI in 2019/20

(Dar es Salaam) IHI invites applications from eligible, competent and qualified companies for the prequalification to provide goods and services for the 2019/2020 financial year. Learn more about this here: …

Recent Projects

Calcium supplementation on pregnant women

Project summary This is a trial-based study funded by the Bill and Melinda Gates Foundation. It intends to generate evidence for decision-making on the potential non-inferiority of a lower dose …

Sustainable, Healthy, Learning Cities and Neighbourhoods

The Sustainable, Healthy, Learning Cities and Neighbourhoods is an exciting project in which IHI works with a consortium of partners from Asia and Africa to 1) develop capacity for improved …

Francis Mhimbira

Research Scientist and Head of Interventions & Clinical Trials

Dr. Francis Mhimbira is an epidemiologist and a research scientist based at Ifakara Health Institute. Dr. Mhimbira received his medical degree at Muhimbili University College of Health Sciences (MUCHS), Tanzania, and did a Masters degree in Epidemiology from The University of Melbourne, Australia. He works within the intervention thematic group and conducts research on TB clinical trials for new drugs and vaccines. His work also involves evaluating new TB diagnostic tools and epidemiological studies on TB and co-infections (such as HIV, helminth and respiratory pathogens). Francis also does operational research to improve TB case detection and improve TB treatment outcomes. He is currently a national and principal investigator of Phase III clinical trial (NC-006) of new TB drugs and regimen. Francis is currently the Head of Interventions and Clinical Trials Department.

View Dr. Mhimbira’s Research Interests and Publications

Projects

Evaluation of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide for treatment of newly-diagnosed TB patients

Evaluation of efficacy, safety and tolerability of a three-drug regimen (Moxifloxacin+PA‐824+Pyrazinamide) for TB and MDR-TB

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016